Literature DB >> 17509559

Modification of alterations in cardiac function and sarcoplasmic reticulum by astragaloside IV in myocardial injury in vivo.

Xiao-Le Xu1, Hui Ji, Shu-Yi Gu, Qin Shao, Qiu-Ju Huang, Yan-Ping Cheng.   

Abstract

Astragaloside IV, the primary pure saponin isolated from Astragalus membranaceus has been found to have potent cardioprotective effects. In this study, we aim to investigate if the beneficial effects of astragaloside IV on cardiac function are associated with improvement in sarcoplasmic reticulum Ca(2+)-pump function in myocardial injury in vivo. Myocardial injury in rats was induced by subcutaneous injection of a high dose of isoproterenol, and the therapeutic effect of astragaloside IV was observed. Isoproterenol-treated rats showed widespread subendocardial necrosis, a rise in serum lactate dehydrogenase and creatine kinase, formation of lipid oxide product malondialdehyde and inhibition of left ventricular diastolic and systolic function, which suggested severe myocardial injury and acute heart failure. Moreover, sarcoplasmic reticulum Ca(2+)-uptake ability and Ca(2+)-ATPase (SERCA2a) activity were significantly reduced. And the level of SERCA2a mRNA and protein expression was also markedly decreased, associated with a decrease in Ser(16)-phosphorylated phospholamban protein expression, while total phospholamban level was unchanged in the isoproterenol-treated group compared with controls. However, these biochemical and hemodynamic changes in the acute failing hearts were prevented by treatment of isoproterenol-induced rats with astragaloside IV. Likewise, the observed reductions in sarcoplasmic reticulum Ca(2+)-pump function as well as in SERCA2a mRNA and protein levels and the phosphorylation level of phospholamban in the injured hearts were attenuated by astragaloside IV treatment. These results suggest that the beneficial effect of astragaloside IV on isoproterenol-induced myocardial injury may be due to its ability to prevent changes of SERCA2a and Ser(16)-phosphorylated phospholamban protein expression and, thus, may prevent the depression in sarcoplasmic reticulum Ca(2+) transport and improve cardiac function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509559     DOI: 10.1016/j.ejphar.2007.04.007

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Research progress on mechanism of action of Radix Astragalus in the treatment of heart failure.

Authors:  Qing-You Yang; Ke-Ji Chen; Shu Lu; Hui-Ru Sun
Journal:  Chin J Integr Med       Date:  2012-04-02       Impact factor: 1.978

2.  Astragaloside IV Inhibits the Inflammatory Injury of Chicken Type II Pneumocytes Induced by Avian Pathogenic Escherichia coli.

Authors:  Li-Yan Zhang; Peng-Fei Yi; Xun Guo; Shuai-Cheng Wu; Yun-Xing Fu; Cui Zhang; Ben-Dong Fu; Hai-Qing Shen; Xu-Bin Wei
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

3.  Tanshinone IIA and astragaloside IV promote the migration of mesenchymal stem cells by up-regulation of CXCR4.

Authors:  Juan Xie; Huan Wang; Tiebing Song; Zongren Wang; Feng Li; Jing Ma; Jun Chen; Yayun Nan; Hui Yi; Wen Wang
Journal:  Protoplasma       Date:  2012-08-08       Impact factor: 3.356

4.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

5.  Arsenic trioxide triggered calcium homeostasis imbalance and induced endoplasmic reticulum stress-mediated apoptosis in adult rat ventricular myocytes.

Authors:  Jing-Yi Zhang; Gui-Bo Sun; Min Wang; Ping Liao; Yu-Yang Du; Ke Yang; Xiao-Bo Sun
Journal:  Toxicol Res (Camb)       Date:  2016-02-08       Impact factor: 3.524

6.  Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway.

Authors:  Xiaoqing Zhang; Huiyan Qu; Tao Yang; Qian Liu; Hua Zhou
Journal:  Cell Cycle       Date:  2022-06-30       Impact factor: 5.173

7.  Astragaloside IV inhibits NF- κ B activation and inflammatory gene expression in LPS-treated mice.

Authors:  Wei-Jian Zhang; Balz Frei
Journal:  Mediators Inflamm       Date:  2015-04-16       Impact factor: 4.711

8.  Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells.

Authors:  Yao Lu; Su Li; Hengfang Wu; Zhiping Bian; Jindan Xu; Chunrong Gu; Xiangjian Chen; Di Yang
Journal:  Int J Mol Med       Date:  2015-09-15       Impact factor: 4.101

9.  Astragaloside IV Attenuates Podocyte Apoptosis Mediated by Endoplasmic Reticulum Stress through Upregulating Sarco/Endoplasmic Reticulum Ca2+-ATPase 2 Expression in Diabetic Nephropathy.

Authors:  Hengjiang Guo; Aili Cao; Shuang Chu; Yi Wang; Yingjun Zang; Xiaodong Mao; Hao Wang; Yunman Wang; Cheng Liu; Xuemei Zhang; Wen Peng
Journal:  Front Pharmacol       Date:  2016-12-21       Impact factor: 5.810

10.  A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease.

Authors:  Xia Wang; Xue Xu; Weiyang Tao; Yan Li; Yonghua Wang; Ling Yang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-29       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.